Alpha-1 Antitrypsin (AAT) is the most abundant circulating serine protease inhibitor and its main function is to protect the lung against proteolytic damage. Little is known about AAT in people living with HIV (PLWH), but in theory: i) AAT may be associated with lower pulmonary function, ii) as an inducer of HIV inhibition in vitro, AAT may be associated with immune status, iii) as an acute phase reactant, AAT may be a novel biomarker for non-AIDS events. We measured AAT in PLWH and in uninfected controls and studied associations with pulmonary function and CD4 T-cell counts.
Using data from the Copenhagen comorbidity in HIV infection (COCOMO) study we assessed AAT levels in PLWH and age and sex matched uninfected controls. Low AAT was defined as below 1.0 g/L. Pulmonary function was measured by spirometry and airflow obstruction was defined by the lower limit of normal (LLN) of FEV1/FVC and by FEV1/FVC<70% plus FEV1-predicted <80% (fixed). We assessed whether AAT to a greater extend contribute to low FEV1-predicted in PLWH than in uninfected controls by studying the interaction between HIV status and AAT in a linear regression model adjusting for age, sex, ethnicity and cumulative smoking. Controlling for the same variables, we assessed whether AAT was associated with current CD4 or CD4 nadir. Finally, we assessed whether HIV was independently associated with AAT controlling for the same variables and hsCRP.
AAT was measured in 1011 PLWH and 11962 uninfected controls with mean (SD) age of 52 (11.5) and predominantly males (81.7%). PLWH had a higher median (interquartile range) AAT: 1.4 [95%CI: 1.3-1.6] vs. 1.3 [1.2-1-4], (p<0.0001). A total of 4.2% [3.1-5.6] PLWH and 6.6% [6.2-7.1] uninfected controls had low levels of AAT (p<0.01). Low AAT were not more common in PLWH with airflow obstruction assessed by LLN (p=0.57) or the fixed criterion (p=0.80). The effect of AAT on FEV1-predicted was similar in PLWH and uninfected controls (p-interaction=0.66). Also, AAT levels (per 1 g/L) did not affect current CD4 (adjusted β=12.2 [-86.2-61.5], p=0.74) or CD4 nadir (adjusted β= 6.7 [-38.9-52.2], p=0.77). HIV status was independently associated with higher AAT levels adjusted β (0.1 [0.01-1.36, p<0.001]).
AAT did not explain the excess pulmonary morbidity previously observed in PLWH. Also, AAT was not associated with immunological status. However, HIV was independently associated with higher levels of AAT and may be an interesting biomarker for other non-AIDS events.